Arthritis Clinical Trials

Study I1F-MC-RHAK is a multicenter study in patients with active rheumatoid arthritis on concomitant conventional disease modifying anti-rheumatic drug (DMARD) therapy. The study is a Phase 2 study with 2 parts. Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design and Part B is an optional, open-label extension design. Two patient populations will be evaluated in this study: biologic disease modifying anti-rheumatic drug [bDMARD]-naive patients and tumor necrosis factor alpha-inadequate responder [TNFα-IR] patients. Patients in Part A receive multiple subcutaneous (SC) injections of LY2439821 (bDMARD-naive patients: 0 [placebo], 3, 10, 30, 80, or 180 mg; TNFα-IR patients: 0 [placebo], 80 or 180 mg) at Weeks 0, 1, 2, 4, 6, 8, and 10. Patients in Part B receive SC injections of LY2439821 160 mg at Weeks 16, 18, and 20, and every 4 weeks thereafter through Week 60. Patients who complete both Part A and B have a total study participation of up to approximately 72 to 84 weeks.